Display options
Cite
Schiattarella GG, Madonna R, Van Linthout S, et al. Epigenetic modulation of vascular diseases: Assessing the evidence and exploring the opportunities. Vascul Pharmacol. 2018;doi: 10.1016/j.vph.2018.02.009.
Schiattarella, G. G., Madonna, R., Van Linthout, S., Thum, T., Schulz, R., Ferdinandy, P., & Perrino, C. (2018). Epigenetic modulation of vascular diseases: Assessing the evidence and exploring the opportunities. Vascular pharmacology, . https://doi.org/10.1016/j.vph.2018.02.009
Schiattarella, Gabriele G, et al. "Epigenetic modulation of vascular diseases: Assessing the evidence and exploring the opportunities." Vascular pharmacology vol. (2018). doi: https://doi.org/10.1016/j.vph.2018.02.009
Schiattarella GG, Madonna R, Van Linthout S, Thum T, Schulz R, Ferdinandy P, Perrino C. Epigenetic modulation of vascular diseases: Assessing the evidence and exploring the opportunities. Vascul Pharmacol. 2018 Mar 14; doi: 10.1016/j.vph.2018.02.009. Epub 2018 Mar 14. PMID: 29548901.
Copy Download .nbib Format: NLM
Share it on

Vascul Pharmacol. 2018 Mar 14; doi: 10.1016/j.vph.2018.02.009. Epub 2018 Mar 14.

Epigenetic modulation of vascular diseases: Assessing the evidence and exploring the opportunities.

Vascular pharmacology

Gabriele G Schiattarella, Rosalinda Madonna, Sophie Van Linthout, Thomas Thum, Rainer Schulz, Peter Ferdinandy, Cinzia Perrino

Affiliations

  1. Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.
  2. Center for Aging Sciences and Translational Medicine - CESI-MeT, Institute of Cardiology, Department of Neurosciences, Imaging and Clinical Sciences, "G. D'Annunzio" University, Chiety, Italy; Center for Cardiovascular Biology and Atherosclerosis Research, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, United States.
  3. Berlin-Brandenburg Center for Regenerative Therapies, Charité, University Medicine Berlin, Campus Virchow, Berlin, Germany; Charité University Medicine Berlin, Campus Rudolf Virchow, Department of Cardiology, Berlin, Germany; DZHK (German Center for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.
  4. Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany.
  5. Institute of Physiology, Justus-Liebig University of Giessen, Giessen, Germany.
  6. Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary; Cardiovascular Research Group, Department of Biochemistry, University of Szeged, Szeged, Hungary; Pharmahungary Group, Szeged, Hungary.
  7. Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy. Electronic address: [email protected].

PMID: 29548901 DOI: 10.1016/j.vph.2018.02.009

Abstract

Vascular adaptations to either physiological or pathophysiological conditions commonly require gene expression modifications in the most represented cellular elements of the vessel wall, i.e. endothelial and smooth muscle cells. In addition to transcription factors, a number of mechanisms contribute to the regulation of gene expression in these cells including noncoding RNAs, histone and DNA modifications, collectively indicated as epigenetic modifications. Here, we summarize the state of art regarding the role of epigenetic changes in major vascular diseases, and discuss the potential diagnostic and therapeutic applications of epigenetic modulation in this context.

Copyright © 2018 Elsevier Inc. All rights reserved.

Keywords: Epigenetics; cardiovascular diseases; endothelial cells; smooth muscle cells

Publication Types